Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.

Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL, Bang YJ, Der CJ.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16868-73. doi: 10.1073/pnas.1306358110. Epub 2013 Sep 30.

2.

DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.

Yang X, Popescu NC, Zimonjic DB.

Cancer Res. 2011 Apr 15;71(8):2916-25. doi: 10.1158/0008-5472.CAN-10-2158. Epub 2011 Mar 3.

3.

E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases.

Asnaghi L, Vass WC, Quadri R, Day PM, Qian X, Braverman R, Papageorge AG, Lowy DR.

Oncogene. 2010 May 13;29(19):2760-71. doi: 10.1038/onc.2010.39. Epub 2010 Mar 15.

4.

Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.

Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI, Lowy DR.

Cancer Res. 2012 Sep 1;72(17):4405-16. doi: 10.1158/0008-5472.CAN-12-0777. Epub 2012 Jun 12.

5.

Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth.

Chung GE, Yoon JH, Lee JH, Kim HY, Myung SJ, Yu SJ, Lee SH, Lee SM, Kim YJ, Lee HS.

Oncol Rep. 2011 Jun;25(6):1739-46. doi: 10.3892/or.2011.1239. Epub 2011 Mar 29.

PMID:
21455586
6.

Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells.

Yuan BZ, Jefferson AM, Millecchia L, Popescu NC, Reynolds SH.

Exp Cell Res. 2007 Nov 1;313(18):3868-80. Epub 2007 Aug 21.

PMID:
17888903
7.

DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.

Healy KD, Hodgson L, Kim TY, Shutes A, Maddileti S, Juliano RL, Hahn KM, Harden TK, Bang YJ, Der CJ.

Mol Carcinog. 2008 May;47(5):326-37.

8.

The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer.

Sabbir MG, Prieditis H, Ravinsky E, Mowat MR.

PLoS One. 2012;7(7):e40302. doi: 10.1371/journal.pone.0040302. Epub 2012 Jul 5.

9.

Fbxw5 suppresses nuclear c-Myb activity via DDB1-Cul4-Rbx1 ligase-mediated sumoylation.

Kanei-Ishii C, Nomura T, Egoh A, Ishii S.

Biochem Biophys Res Commun. 2012 Sep 14;426(1):59-64. doi: 10.1016/j.bbrc.2012.08.032. Epub 2012 Aug 14.

PMID:
22910413
10.

DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.

Tripathi V, Popescu NC, Zimonjic DB.

Oncogene. 2014 Feb 6;33(6):724-33. doi: 10.1038/onc.2013.7. Epub 2013 Feb 4.

PMID:
23376848
11.

Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.

Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, Jin DY, Ng IO.

Cancer Res. 2005 Oct 1;65(19):8861-8.

12.

C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer.

Shi Y, Chen J, Li Z, Zhang Z, Yu H, Sun K, Wang X, Song X, Wang Y, Zhen Y, Yang T, Lou K, Zhang Y, Zhang G, Hu Y, Ji J, Hui R.

Oncogene. 2011 Sep 29;30(39):4107-17. doi: 10.1038/onc.2011.116. Epub 2011 Apr 18.

PMID:
21499297
13.

The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1.

Muehlich S, Hampl V, Khalid S, Singer S, Frank N, Breuhahn K, Gudermann T, Prywes R.

Oncogene. 2012 Aug 30;31(35):3913-23. doi: 10.1038/onc.2011.560. Epub 2011 Dec 5.

PMID:
22139079
14.

Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.

Cao X, Voss C, Zhao B, Kaneko T, Li SS.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1455-60. doi: 10.1073/pnas.1114368109. Epub 2012 Jan 17. Erratum in: Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4708.

15.

DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway.

Ullmannova-Benson V, Guan M, Zhou X, Tripathi V, Yang XY, Zimonjic DB, Popescu NC.

Leukemia. 2009 Feb;23(2):383-90. doi: 10.1038/leu.2008.285. Epub 2008 Oct 16.

16.

Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.

Yam JW, Ko FC, Chan CY, Jin DY, Ng IO.

Cancer Res. 2006 Sep 1;66(17):8367-72.

17.

Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).

Li G, Du X, Vass WC, Papageorge AG, Lowy DR, Qian X.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17129-34. doi: 10.1073/pnas.1112122108. Epub 2011 Oct 3.

18.

Promoter methylation of the DLC‑1 gene and its inhibitory effect on human colon cancer.

Dai Z, Jin Y.

Oncol Rep. 2013 Sep;30(3):1511-7. doi: 10.3892/or.2013.2551. Epub 2013 Jun 19.

PMID:
23783552
19.

WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase.

Hu J, Zacharek S, He YJ, Lee H, Shumway S, Duronio RJ, Xiong Y.

Genes Dev. 2008 Apr 1;22(7):866-71. doi: 10.1101/gad.1624008.

20.

H2O2 inhibits proliferation and mediates suppression of migration via DLC1/RhoA signaling in cancer cells.

Ma L, Zhu WZ, Liu TT, Fu HL, Liu ZJ, Yang BW, Song TY, Li GR.

Asian Pac J Cancer Prev. 2015;16(4):1637-42.

Items per page

Supplemental Content

Write to the Help Desk